The Brazilian pharmaceutical market is mainly out-of-pocket and hard to afford for most of the public.
To grant access to medicines to a broader section of the population and to provide them with better treatment options, we are developing innovative business models together with the public sector.
|Pharmaceutical business environment||- For 80 % of medicines people have to make additional payments. Copnsequently, the poorer classes often have difficultiues accessing medical care. Generics are increasing rapidly and today account for 20 % of the Brazilian pharmaceutical market. This is also linked to the looser patent regulations. Stroke is the No.1 cause of death in Brazil. Hence the greater need of innovative medicines.
- The most urgent satisfaction of medical needs is being achieved. Indispensable medicines are on the government list.
|Size||USD 22.788 billion (IMS)|
|Development||- The share of expenditure on medicines is increasing (in relation to total healthcare expenditure). That shows that the healthcare system and access to medical treatment are being attributed greater importance by the government.
- The government has initiated the “Farmacia Popular do Brasil” programme in order to supply poorer citizens with medicines. Many, who still have no access to medicines, are increasingly demanding that the government supplies innovative medicines which they have so far had to pay for themselves
- Fake medicines are on the increase; their market share is estimated at around 30 %.
|Obstacles, e.g. market regulation||- For the research-driven pharmaceutical industry Brazil is one of the most problematical regions:
slow scrutiny of patents, conflicts between both authorities involved in awarding patents.
|Market for prescription medicines and over-the-counter medications||In 2008, 12.2 % of expenditure in the healthcare system was used for prescription medicines (Datamonitor 2010).|